Management of AIDS-related Kaposi's sarcoma

Lancet Oncology

Volumn 8, Issue 2, 2007, Pages 167-176

  Di Lorenzo, Giuseppe ^b   Konstantinopoulos, Panagiotis A ^a   Pantanowitz, Liron ^c   Di Trolio, Rossella ^b   De Placido, Sabino ^b   Dezube, Bruce J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BEVACIZUMAB; BLEOMYCIN; CORTICOSTEROID; CYTOTOXIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DIDANOSINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; IMATINIB; IMMUNOMODULATING AGENT; LIPOSOME; PACLITAXEL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SORAFENIB; TAXANE DERIVATIVE; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; APPLICATION SITE DISCOLORATION; APPLICATION SITE REACTION; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CARDIOMYOPATHY; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; KAPOSI SARCOMA; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SKIN IRRITATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; SARCOMA, KAPOSI;

EID: 33846473044     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70036-0     Document Type: Review

References (81)

1. Engels E., Pfeiffer R., Goedert J., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
2. Cheung M., Pantanowitz L., and Dezube B. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10 (2005) 412-426
3. Dezube B., Pantanowitz L., and Aboulafia D. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 14 (2004) 236-238 243-4, 251-3.
4. Mwanda O., Fu P., Collea R., et al. Kaposi's sarcoma in patients with and without human immunodeficiency virus infection, in a tertiary referral centre in Kenya. Ann Trop Med Parasitol 99 (2005) 81-91
5. Nichols C., Flaitz C., and Hicks M. Treating Kaposi's lesions in the HIV-infected patient. J Am Dent Assoc 124 (1993) 78-84
6. Ioachim H., Adsay V., Giancotti F., et al. Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases. Cancer 75 (1995) 1376-1385
7. Gruden J., Huang L., Webb W., et al. AIDS-related Kaposi sarcoma of the lung: radiographic findings and staging system with bronchoscopic correlation. Radiology 195 (1995) 545-552
8. Krown S., Metroka C., and Wernz J. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7 (1989) 1201-1207
9. Nasti G., Talamini R., Antinori A., et al. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 21 (2003) 2876-2882
10. Stebbing J., Sanitt A., Nelson M., et al. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 367 (2006) 1495-1502
11. Krown S. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 22 (2004) 399-402
12. Eng W., and Cockerell C. Histological features of kaposi sarcoma in a patient receiving highly active antiviral therapy. Am J Dermatopathol 26 (2004) 127-132
13. Cattelan A., Calabro M., Aversa S., et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 35 (1999) 1809-1815
14. Cattelan A., Calabro M., Gasperini P., et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 28 (2001) 44-49
15. Pati S., Pelser C., Dufraine J., et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99 (2002) 3771-3779
16. Sgadari C., Barillari G., Toschi E., et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8 (2002) 225-232
17. Stebbing J., Portsmouth S., and Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma?. J Antimicrob Chemother 51 (2003) 1095-1098
18. Stebbing J., Portsmouth S., Gotch F., and Gazzard B. Kaposi's sarcoma-an update. Int J STD AIDS 14 (2003) 225-227
19. Ledergerber B., Telenti A., and Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. BMJ 319 (1999) 23-24
20. Grabar S., Abraham B., Mahamat A., et al. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 24 (2006) 3408-3414
21. Portsmouth S., Stebbing J., Gill J., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. Aids 17 (2003) F17-F22
22. Bower M., Fox P., Fife K., et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. Aids 13 (1999) 2105-2111
23. Lipman M., and Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 19 (2006) 20-25
24. Bower M., Nelson M., Young A., et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 23 (2005) 5224-5228
25. Connick E., Kane M., White I., et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 39 (2004) 1852-1855
26. Gressen E., Rosenstock J., Xie Y., and Corn B. Palliative treatment of epidemic Kaposi sarcoma of the feet. Am J Clin Oncol 22 (1999) 286-290
27. Swift P. The role of radiation therapy in the management of HIV-related Kaposi's sarcoma. Hematol Oncol Clin North Am 10 (1996) 1069-1080
28. Kigula-Mugambe J., and Kavuma A. Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. Radiother Oncol 76 (2005) 59-62
29. Kirova Y., Belembaogo E., Frikha H., et al. Radiotherapy in the management of epidemic Kaposi's sarcoma: a retrospective study of 643 cases. Radiother Oncol 46 (1998) 19-22
30. Yildiz F., Genc M., Akyurek S., et al. Radiotherapy in the management of Kaposi's sarcoma: comparison of 8 Gy versus 6 Gy. J Natl Med Assoc 98 (2006) 1136-1139
31. Macklis R. Atypical radiation toxicity in patients with classical Kaposi's sarcoma. Tumori 77 (1991) 491-495
32. Becker G., and Bottke D. Radiotherapy in the management of Kaposi's sarcoma. Onkologie 29 (2006) 329-333
33. Walmsley S., Northfelt D., Melosky B., et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 22 (1999) 235-246
34. Ramirez-Amador V., Esquivel-Pedraza L., Lozada-Nur F., et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 38 (2002) 460-467
35. Tappero J., Berger T., Kaplan L., Volberding P., and Kahn J. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr 4 (1991) 839-846
36. Hebeda K., Huizing M., Brouwer P., et al. Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995) 61-70
37. Bernstein Z., Wilson B., Oseroff A., et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. Aids 13 (1999) 1697-1704
38. Allen T., and Martin F. Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 31 6 Suppl 13 (2004) 5-15
39. Northfelt D., Dezube B., Thommes J., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16 (1998) 2445-2451
40. Osoba D., Northfelt D., Budd D., and Himmelberger D. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest 19 (2001) 573-580
41. Stewart S., Jablonowski H., Goebel F., et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16 (1998) 683-691
42. Gill P., Wernz J., Scadden D., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14 (1996) 2353-2364
43. Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. The Oncologist (in press).
44. Lichterfeld M., Qurishi N., Hoffmann C., et al. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection 33 (2005) 140-147
45. Hofheinz R., Gnad-Vogt S., Beyer U., and Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 16 (2005) 691-707
46. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2 (1996) 1843-1849
47. Tulpule A., Groopman J., Saville M., et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95 (2002) 147-154
48. Welles L., Saville M., Lietzau J., et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 16 (1998) 1112-1121
49. Hudnall S., Rady P., Tyring S., and Fish J. Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. J Infect Dis 178 (1998) 1791-1794
50. Lim S., Tupule A., Espina B., and Levine A. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 103 (2005) 417-421
51. Autier J., Picard-Dahan C., Marinho E., et al. Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study. Br J Dermatol 152 (2005) 1026-1029
52. Krown S., Li P., Von Roenn J., et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 22 (2002) 295-303
53. Shepherd F., Beaulieu R., Gelmon K., et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 16 (1998) 1736-1742
54. Kreuter A., Rasokat H., Klouche M., et al. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 23 (2005) 653-659
55. Dupin N., Fisher C., Kellam P., et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96 (1999) 4546-4551
56. Dourmishev L., Dourmishev A., Palmeri D., et al. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67 (2003) 175-212 table of contents.
57. Nicholas J., Ruvolo V., Burns W., et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 3 (1997) 287-292
58. Tirelli U., Bernardi D., Spina M., and Vaccher E. AIDS-related tumors: integrating antiviral and anticancer therapy. Crit Rev Oncol Hematol 41 (2002) 299-315
59. Mesri E. Inflammatory reactivation and angiogenicity of Kaposi's sarcoma-associated herpesvirus/HHV8: a missing link in the pathogenesis of acquired immunodeficiency syndrome-associated Kaposi's sarcoma. Blood 93 (1999) 4031-4033
60. Folpe A., Veikkola T., Valtola R., and Weiss S. Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 13 (2000) 180-185
61. Masood R., Cesarman E., Smith D., et al. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 160 (2002) 23-29
62. Skobe M., Brown L., Tognazzi K., et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 113 (1999) 1047-1053
63. Bais C., Van Geelen A., Eroles P., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3 (2003) 131-143
64. Aoki Y., Jaffe E., Chang Y., et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93 (1999) 4034-4043
65. Little R., Wyvill K., Pluda J., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18 (2000) 2593-2602
66. Dezube B., Von Roenn J., Holden-Wiltse J., et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 16 (1998) 1444-1449
67. Pistritto G., Ventura L., Mores N., et al. Regulation of PDGF-B and PDGF receptor expression in the pathogenesis of Kaposi's sarcoma in AIDS. Antibiot Chemother 46 (1994) 73-87
68. Sturzl M., Roth W., Brockmeyer N., et al. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 89 (1992) 7046-7050
69. Moses A., Jarvis M., Raggo C., et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 76 (2002) 8383-8399
70. Koon H., Bubley G., Pantanowitz L., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23 (2005) 982-989
71. Impola U., Cuccuru M., Masala M., et al. Preliminary communication: matrix metalloproteinases in Kaposi's sarcoma. Br J Dermatol 149 (2003) 905-907
72. Lafrenie R., Wahl L., Epstein J., et al. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 156 (1996) 1638-1645
73. Blankaert D., Simonart T., Van Vooren J., et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 18 (1998) 203-209
74. Hidalgo M., and Eckhardt S. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93 (2001) 178-193
75. Dezube B., Krown S., Lee J., et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24 (2006) 1389-1394
76. Sullivan R., Dezube B., and Koon H. Signal transduction in Kaposi's sarcoma. Curr Opin Oncol 18 (2006) 456-462
77. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
78. Kedes D., and Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99 (1997) 2082-2086
79. Glesby M., Hoover D., Weng S., et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 173 (1996) 1477-1480
80. Pantanowitz L., and Dezube B. Kaposi sarcoma of the larynx. AIDS Read 16 (2006) 194-195
81. Huang W., Pantanowitz L., and Dezube B. Unusual Sites of Malignancies: CASE 3. AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol 23 (2005) 2098-2099